EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol

Lana Ghanipour iD, Gabriella Jansson Palmer, Per J Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog iD, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal und 2 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0294018 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Lana Ghanipour und 13 weiteren Autor:innen. Beteiligte Einrichtung: Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Standard treatment for patient with peritoneal metastases from colorectal cancer is cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). In recent years, the efficacy of oxaliplatin-based HIPEC has been challenged. An intensified HIPEC (oxaliplatin+irinotecan) in combination with early postoperative intraperitoneal chemotherapy (EPIC) has shown increased recurrence-free survival in retrospective studies. The aim of this trial is to develop a new HIPEC/EPIC regimen and evaluate its effect on morbidity, oncological outcome, and quality-of-life (QoL). This study is designed as a combined phase I/III multicenter randomized trial (RCT) of patients with peritoneal metastases from colorectal cancer eligible for CRS-HIPEC. An initial phase I dose escalation study, designed as a 3+3 stepwise escalation, will determine the maximum tolerable dose of 5-Fluorouracil (5-FU) as 1-day EPIC, enrolling a total of 15–30 patients in 5 dose levels. In the phase III efficacy study, patients are randomly assigned intraoperatively to either the standard treatment with oxaliplatin HIPEC (control arm) or oxaliplatin/irinotecan-HIPEC in combination with single dose of 1-day 5-FU EPIC (experimental arm). 5-FU is administered intraoperatively after CRS-HIPEC and closure of the abdomen. The primary endpoint is 12-month recurrence-free survival. Secondary endpoints include 5-year overall survival, 5-year recurrence-free survival (registry based), postoperative complications, and QoL up to 3 years after study treatment. This phase I/III trial aims to identify a more effective treatment of colorectal peritoneal metastases by combination of HIPEC and EPIC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPeritoneal NeoplasmsHumansClinical Trials, Phase I as TopicFluorouracilHyperthermic Intraperitoneal ChemotherapyIrinotecanMulticenter Studies as TopicOxaliplatinQuality of LifeRandomized Controlled Trials as TopicRegistriesRetrospective StudiesClinical Trials, Phase III as Topic

Substanzen

FluorouracilIrinotecanOxaliplatin

Autor:innen und Institutionen

  • Uppsala University, Uppsala, Sweden.
  • Department of Surgical Sciences, Gastro Intestinal Surgery, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
  • Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden.

ORCID-Profile: Lana Ghanipour, Elinor Bexe Lindskog

Förderung

  • Vetenskapsrådet

Zitieren

APA

Ghanipour, L., Jansson Palmer, G., Nilsson, P. J., Nordenvall, C., Frödin, J. E., Bexe Lindskog, E., Asplund, D., Swartling, T., Graf, W., Birgisson, H., Syk, I., Verwaal, V., Brändstedt, J., & Cashin, P. H. (2024). Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0294018

Vancouver

Ghanipour L, Jansson Palmer G, Nilsson PJ, Nordenvall C, Frödin JE, Bexe Lindskog E, et al. Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol. PLOS ONE. 2024. doi:10.1371/journal.pone.0294018

BibTeX
@article{Ghanipour2024,
  author = {Ghanipour, Lana and Jansson Palmer, Gabriella and Nilsson, Per J and Nordenvall, Caroline and Frödin, Jan-Erik and Bexe Lindskog, Elinor and Asplund, Dan and Swartling, Torbjörn and Graf, Wilhelm and Birgisson, Helgi and Syk, Ingvar and Verwaal, Victor and Brändstedt, Jenny and Cashin, Peter H},
  title = {Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0294018}
}
Kostenlos starten →